SCHEMBL658947

SCHEMBL658947

CCNc1nc2cccc(B3OC(C)(C)C(C)(C)O3)c2s1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.48
NPC1 O15118 5/20 0.36
RAB9A P51151 4/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
LPL P06858 3/20 0.33
LIPG Q9Y5X9 3/20 0.33
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
CCNA2 P20248 1/20 0.32
CDK2 P24941 1/20 0.32
TBXAS1 P24557 3/20 0.32
SHMT2 P34897 1/20 0.32
MAPK14 Q16539 1/20 0.31
CRHR1 P34998 1/20 0.31
ELANE P08246 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL660264 0.85 APP (0.33) POLBNPC1RAB9ASMN1; SMN2LPL
SCHEMBL32691558 0.79 HSD17B10 (0.36) NPC1RAB9ASMN1; SMN2LPLLIPG
SCHEMBL32691384 0.78 ASH1L (0.36) RAB9ASMN1; SMN2LPLLIPGALDH1A1
SCHEMBL31557364 0.76 NPC1 (0.48) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL659295 0.76 KDM4E (0.40) NPC1RAB9ASMN1; SMN2LPLLIPG
SCHEMBL658951 0.75 NPC1 (0.33) NPC1RAB9ASMN1; SMN2LPLLIPG
SCHEMBL29311378 0.75 LPL (0.42) NPC1RAB9ASMN1; SMN2LPLLIPG
SCHEMBL659501 0.71 POLB (0.54) POLBNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL21685796 0.71 DGAT1 (0.39) NPC1RAB9ASMN1; SMN2LPLLIPG
SCHEMBL660323 0.69 LPL (0.35) LPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8378104-B2 7-aminofuropyridine derivatives OSI Pharmaceuticals, LLC (US) 2013-02-19 US disclosed
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI PHARMACEUTICALS, INC. 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES MAP3K5, STK17A, MAPKAPK5 POLB 4297/4885NPC1 976/4885RAB9A 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.